Navigation Links
FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

The Food and Drug Administration (FDA) today announced a series of important changes pertaining to the marketing of the non-steroidal anti-inflammatory class of drugs, including COX-2 selective and prescription and non-prescription (over-the-counter (OTC)) non-selective NSAID medications. A list of these products is available on the Internet at http://www.fda.gov/cder/drug/infopage/cox2/default.htm.

"Today's actions protect and advance the health of the millions of Americans who rely on these drugs everyday," said Dr. Steven K. Galson, Acting Director of FDA's Center for Drug Evaluation and Research (CDER). "FDA is providing the public information based on the latest available scientific data to guide the careful and appropriate use of these drugs aimed at maximizing their potential benefits and minimizing their risks."

FDA has asked Pfizer, Inc. to withdraw Bextra (valdecoxib) from the market because the overall risk versus benefit profile for the drug is unfavorable. FDA has also asked Pfizer to include a boxed warning in the Celebrex (celecoxib) label. Pfizer has agreed to suspend sales and marketing of Bextra in the U.S., pending further discussions with the agency. Pfizer has agreed to work with FDA on the boxed warning for Celebrex. FDA is asking manufacturers of all other prescription NSAIDs to revise their labels to include the same boxed warning highlighting the potential for increased risk of cardiovascular (CV) events and gastrointestinal (GI) bleeding associated with their use. Manufacturers of Celebrex and all other prescription NSAIDs will be asked to revise their labeling to include a Medication Guide for patients to help make them aware of the potential for CV and GI adverse events associated with the use of this class of drugs.

In addition, FDA is asking the manufacturers of all OTC NSAIDs to revise their labels to include more specific information about the potential CV and GI risks, and information to assist consumers in the
'"/>

Source:FDA


Page: 1 2

Related biology news :

1. Ariadne Genomics Announces the Release of PathwayStudio?Central, Client-Server Software for Biological Pathway Analysis
2. Iron Deficiency Sparks Dramatic Changes In Gene Expression
3. Scientists Propose Sweeping Changes to Naming of Bird Neurosystems to Acknowledge Their True Brainpower
4. Methamphetamine Abuse, HIV Infection Cause Changes in Brain Structure
5. Changes to embryos can elicit change in adult fish
6. Changes in amino acids in the 1918 influenza virus cut transmission
7. PANTHER Protein Classification System Database 5.0
8. FDA Warns Consumers Not to Use Home-Use Diagnostic Kits Marketed by Globus Media
9. HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs
10. New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal
11. FDA Warns About Antipsychotic Drugs and Elderly
Post Your Comments:
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button Synaptics ... http://photos.prnewswire.com/prnh/20130307/600769 ... iPhone 5S, Samsung introduces for the first time a ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally transforming ... than at international borders. Over the past decade, ePassports, ... travelers to self process through border control via eGates ... number of airports, seaports, and land borders across the ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... University of California, Santa Cruz, who pioneered the use of ... compiled one of the largest datasets available for any marine ... in unprecedented detail. A new study published May ... the annual migrations of adult female elephant seals, with data ...
... Inc. (NASDAQ: AWRE ), a global provider ... it is providing biometrics software and services for three ... team-based project wins in Europe, the Middle East, and ... provide system integrators with a full suite of COTS ...
... drug made from the saliva of the Gila monster ... Researchers at the Sahlgrenska Academy, University of Gothenburg, have ... their cravings for both food and chocolate. An ... are offered a pharmaceutical preparation called Exenatide, which helps ...
Cached Biology News:Elephant seal tracking reveals hidden lives of deep-diving animals 2Elephant seal tracking reveals hidden lives of deep-diving animals 3Aware Provides Biometrics Software and Services for Three Large-Scale Border Management Systems 2Aware Provides Biometrics Software and Services for Three Large-Scale Border Management Systems 3Drugs from lizard saliva reduces the cravings for food 2
(Date:1/22/2015)... 2015 zFlo Motion , a US ... an exciting product from a new partner. STT-Systems ... the past 15 years, with offerings in the optical-motion capture, ... IMU system (inertial measurement unit), iSen, is opening eyes around ...
(Date:1/22/2015)... 2015 Controlled Substance Compliance Services (CSCS), ... companies check the legal requirements around using controlled substances ... , As their international operations expand and become ... solutions built as a result of the first phase ...
(Date:1/22/2015)... January 22, 2015 Diagenode, Inc., ... as the Bioruptor® and complete solutions for epigenetics ... chromatin immunoprecipitation, alleviating the need for manual processing. ... needed for ChIP of histones or transcription factors ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Global Compliance Service for Controlled Substances to Expand to China 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
... Pharmasset, Inc. (Nasdaq: VRUS ) announced today ... the FDA on the final design for a phase 2b ... slated to initiate in the first quarter of this year."We ... 2b trial," stated Michelle Berrey, MD, MPH, Pharmasset,s Chief Medical ...
... Special Meeting to Enable Stockholders to Determine Fate ... Inc. Offers Avigen Stockholders Extraordinary Risk/Reward OpportunitySAN FRANCISCO, ... with its affiliates ("BVF") today announced that it ... Avigen, Inc. ("Avigen") (Nasdaq: AVGN ) ...
... VANCOUVER, Jan. 9 /PRNewswire/ - Sirius Genomics, a ... has signed a collaborative agreement with the United ... focuses on the continued development of Sirius, pharmacogenomic ... (sold by Eli Lilly and Company under the ...
Cached Biology Technology:Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 2Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 3Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 4Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 5Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees 2Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees 3Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees 4Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees 5Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group 2
geminin, DNA replication inhibitor...
Normal human serum, single donor...
One-step, microplate or cuvet, colorimetric, linear detection range 0.1 mg/dL to 100 mg/dL. Procedure: 20 min....
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
Biology Products: